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Abstract Acute liver failure is a clinical syndrome
characterized by hepatic encephalopathy and a bleeding
tendency due to severe impairment of liver function caused
by massive or submassive liver necrosis. Viral hepatitis is
the most important and frequent cause of acute liver failure
in Japan. The diagnostic criteria for fulminant hepatitis,
including that caused by viral infections, autoimmune
hepatitis, and drug allergy induced-liver damage, were first
established in 1981. Considering the discrepancies between
the definition of fulminant hepatitis in Japan and the defi-
nitions of acute liver failure in the United States and Eur-
ope, the Intractable Hepato-Biliary Disease Study Group
established the diagnostic criteria for ‘‘acute liver failure’’
for Japan in 2011, and performed a nationwide survey of
patients seen in 2010 to clarify the demographic and clin-
ical features and outcomes of these patients. According to
the survey, the survival rates of patients receiving medical
treatment alone were low, especially in those with hepatic
encephalopathy, despite artificial liver support, consisting
of plasma exchange and hemodiafiltration, being provided
to almost all patients in Japan. Thus, liver transplantation is
inevitable to rescue most patients with hepatic encepha-
lopathy. The indications for liver transplantation had, until
recently, been determined according to the guideline pub-
lished by the Acute Liver Failure Study Group in 1996.
Recently, however, the Intractable Hepato-Biliary Disease
Study Group established a scoring system to predict the
outcomes of acute liver failure patients. Algorithms for
outcome prediction have also been developed based on
data-mining analyses. These novel guidelines need further
evaluation to determine their usefulness.
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Introduction
Liver failure is a clinical syndrome characterized by
jaundice, ascites, hepatic encephalopathy, and a bleeding
tendency due to impairment of liver function; the syndrome
can be caused by conditions such as viral hepatitis, auto-
immune hepatitis, drug-induced liver injuries, metabolic
diseases, and circulatory disturbances. Liver failure has
been classified into 2 types, depending on the clinical
course; namely, acute liver failure and chronic liver failure.
In general, acute liver failure is diagnosed in patients in
whom severe liver function impairment, as judged from the
clinical symptoms, laboratory data, and imaging examin-
ations, develops within 24 or 26 weeks (6 months) fol-
lowing the onset of liver injury in a preexisting normal
liver, while chronic liver failure is diagnosed in patients
with persistent liver inflammation and injuries who show
liver function impairment later than 6 months after the
onset of the liver symptoms.
Worldwide, the representative disease entity associated
with chronic liver failure is liver cirrhosis due to persistent
hepatitis virus infection, autoimmune hepatitis, or hepatitis
of indeterminate etiology. However, the demographic and
clinical features of acute liver failure differ between Japan
and Europe or the United States. Hepatitis viral infection is
the most important and common cause of acute liver failure
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in Japan [1], while drug-induced liver injury, including
acetaminophen intoxication, is the major cause of acute
liver failure in Europe and the United States [2]. Thus,
acute liver failure is typically associated with fulminant
viral hepatitis in Japan, and the diagnostic criteria for
‘‘fulminant hepatitis’’, which are different from those for
‘‘acute liver failure’’ in Europe and the United States, were
first established at the Inuyama Symposium in 1981 [3].
The therapeutic strategies for acute liver failure also
differ between Japan and Europe and/or the United States.
Cadaveric transplantation is considered as the first-line
therapy for acute liver failure in Europe and the United
States [2], while in Japan, artificial liver support, consisting
of plasma exchange and hemodiafiltration, is usually pro-
vided first to patients with fulminant hepatitis [1], and liver
transplantation, usually from living donors [4–6], is only
scheduled when no clinical improvement is achieved with
this conventional medical treatment [1]. Thus, the criteria
for scheduling liver transplantation for patients with acute
liver failure and/or fulminant hepatitis also differ between
Japan and other countries.
In the present article, we discuss in detail the differences
between Japan and Europe and/or the United States in the
definitions, classifications, and diagnostic criteria for the
disease subtypes of acute liver failure and/or fulminant
hepatitis, and also the indications for liver transplantation
in these patients. Also, we describe the clinical features of
patients with acute liver failure in Japan, which were
analyzed through a nationwide survey conducted using the
diagnostic criteria revised in 2011 in reference to those in
Europe and the United States.
Diagnostic criteria for acute liver failure in Europe,
the United States, and Asian countries other than Japan
Epidemic hepatitis was a worldwide health problem in the
early twentieth century, and it was already known, even in
the 1920s, that differences existed in the clinical course
even among patients with the fatal form of the disease, and
that patients could be divided into those with fulminant,
acute, or chronic forms [7]. Although most patients with
fatal disease exhibited a subacute clinical course, with the
patients dying between 4 and 6 weeks after the onset of the
hepatitis symptoms, a patient showing a more rapid course
was first reported in the great Swedish epidemic in 1927
[8]. This was the first case report of fulminant-type epi-
demic hepatitis although it was thought that such patients
were seldom encountered elsewhere in the world. How-
ever, the concept of epidemic hepatitis changed with the
occurrence of World War II; epidemic hepatitis changed to
a hepatitis pandemic during World War II, with large
outbreaks occurring in many parts of the world, especially
in armies. Lucke and Mallory [7] reported on the outbreak
of epidemic hepatitis in the United States Army between
August 1943 and April 1945, in which 104 of 196 patients
(53 %) had a fatal course and died within 10 days of the
onset of the hepatitis symptoms. Lucke and Mallory named
this form of hepatitis, which was probably caused by
hepatitis A virus (HAV) or hepatitis E virus (HEV)
infection, the ‘‘fulminant form’’ of hepatitis.
By the end of World War II, the hepatitis pandemic had
not spread to any extent in Europe or the United States, and
the ‘‘fulminant form of hepatitis’’ was recognized as an
infrequent, but intractable, disease in Western countries.
Also, advances in the field of virology in the 1970s enabled
hepatologists to evaluate patients with fulminant hepatitis
for serum markers of HAV and hepatitis B virus (HBV)
infection, and these two types of hepatitis viruses were
found to account for a large proportion of the patients
[9–11]. On the other hand, Trey et al. [12] reported that
drugs such as halothane may also cause acute liver disease,
similar in clinical course to fulminant hepatitis. They
evaluated the etiology in 150 patients enrolled from 73
centers, and revealed that the cause of the hepatitis was
presumed viral hepatitis in 70 patients (46.7 %) (including
serum hepatitis and epidemic hepatitis in 24 and 46
patients, respectively), and drug-induced liver disease in 48
patients (32.0 %) (including 36 with halothane exposure as
the culprit) [12]. These observations prompted hepatolo-
gists to use the nomenclature of ‘‘fulminant hepatic
failure’’ instead of ‘‘fulminant hepatitis’’ for patients pre-
senting with acute onset of massive liver necrosis. Then, in
1970, Trey and Davidson [13] proposed the now well-
known diagnostic criteria for fulminant hepatic failure;
they defined the condition as a clinical syndrome charac-
terized by massive liver necrosis associated with severe
impairment of hepatic function, manifesting as progressive
jaundice, hepatic coma, and liver atrophy developing
within 8 weeks of the onset of the first symptoms of the
disease in individuals with no previous history of hepatic
disease. Moreover, in 1986, Gimson et al. [14] suggested
that patients showing hepatic encephalopathy as well as
other evidence of hepatic decompensation developing more
than 8 weeks but less than 24 weeks of the onset of the first
symptoms be labeled as having late-onset hepatic failure
(LOHF), a clinical syndrome related to fulminant hepatic
failure.
In contrast, in France, Bernuau et al. [15] proposed the
nomenclature of ‘‘fulminant and subfulminant liver fail-
ure’’ for patients with rapidly progressive hepatic failure;
patients developing hepatic encephalopathy less than
2 weeks after the onset of jaundice were diagnosed as
having fulminant liver failure, while those with hepatic
encephalopathy developing between 2 and 12 weeks after
the onset of jaundice were labeled as having subfulminant
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liver failure. Also, the terminology of ‘‘subacute liver
failure’’ was introduced in India in 1982 for patients
showing progressive jaundice with ascites of 8 weeks’
duration, with otherwise typical features of acute viral
hepatitis; the presence of hepatic encephalopathy was not a
necessary criterion for the diagnosis of this condition [16].
While intense debate still continues on the definition and
classification of patients showing rapid progression of
hepatic failure, all hepatologists around the world, includ-
ing those in Japan [17], agree that patients showing the
most rapid onset of hepatic encephalopathy have the best
chance of recovery with conventional medical treatment.
Although geographic heterogeneity was found in the
etiology and clinical features of acute liver diseases, stan-
dardization of the nomenclature and diagnostic criteria for
patients showing rapidly progressive hepatic failure is
required for reliable comparisons of the efficacies of
various treatments and of the resultant outcomes among
different countries.
Thus, in 1993, O’Grady et al. [18] redefined such syn-
dromes as ‘‘acute liver failure’’ prefixed with ‘‘hyper’’ and
‘‘sub’’ to describe 2 cohorts at opposite ends of the clinical
spectrum, based on the observation of a large series of
patients treated at King’s College Hospital, London,
between 1972 and 1985. According to this proposed clas-
sification, patients with hepatic encephalopathy developing
within 7 days of the onset of jaundice are diagnosed as
having ‘‘hyperacute liver failure’’, which is often caused by
acetaminophen intoxication [18]. In contrast, patients
showing hepatic encephalopathy between 8 and 28 days
and those with encephalopathy developing later than
28 days after the first onset of symptoms were diagnosed as
having ‘‘acute liver failure’’ and ‘‘subacute liver failure’’,
respectively, with HAV or HBV infection and drug-
induced liver damage being more frequently seen in the
former cohort, and liver disease of indeterminate etiology
being seen more frequently in the latter cohort [18]. It
should be noted that patients with pre-existing symptom-
less chronic liver diseases were included in the disease
entity of ‘‘acute liver failure’’ by O’Grady et al. [18], and in
that of ‘‘fulminant liver failure’’ by Bernuau et al. [15],
while such patients were excluded from the entity of
‘‘fulminant hepatic failure’’ by Trey and Davidson [13].
Criticisms were raised regarding the nomenclature and
definition of ‘‘acute liver failure’’ proposed by the King’
College Hospital group, especially in France [19] and India
[20]. Thus, the subcommittee of the International Associ-
ation for the Study of the Liver (IASL) published revised
recommendations on the nomenclature of acute and suba-
cute hepatic failure in 1999 [21]. In this recommendation,
two distinct disease entities, but not subgroups of a syn-
drome, were established; namely, ‘‘acute hepatic failure’’
and ‘‘subacute hepatic failure’’. Patients without pre-
existing liver disease developing hepatic encephalopathy
within 4 weeks of the onset of the disease symptoms are
diagnosed as having acute hepatic failure. Acute hepatic
failure is a potentially reversible liver disease and is clas-
sified into hyperacute and fulminant forms, defined by the
development of hepatic encephalopathy less than 10 days
and between 10 and 30 days, respectively, after the first
onset of the disease symptoms. In contrast, patients
developing hepatic encephalopathy between the 5th and
24th weeks after the first onset of symptoms are diagnosed
as having subacute hepatic failure.
Consequently, until the beginning of the twenty-first
century, hepatitis showing rapid progression was referred
to by various names, including fulminant hepatitis [7],
fulminant hepatic failure [13], fulminant liver failure [15],
acute liver failure [18], and acute hepatic failure [21]
(Table 1). However, ‘‘acute liver failure’’ came to be used
predominantly as the most suitable umbrella term, because
it can be assumed to include all of the other disease entities
[22]. Thus, the Practice Guideline Committee of the
American Association for the Study of Liver Diseases
(AASLD) published a position paper for the management
of ‘‘acute liver failure’’ in 2005 [2]. Acute liver failure is
defined as ‘‘liver diseases characterized by the develop-
ment of hepatic encephalopathy and coagulation abnor-
malities, usually characterized by an international
normalized ratio (INR) of 1.5 or more, in patients without
preexisting cirrhosis, and an illness of less than 26 weeks
duration’’. In this position paper, subgroups classified
according to the interval between the onset of hepatic
encephalopathy and the first onset of the disease symp-
toms; namely, the hyperacute, acute, and subacute types,
were shown to be not helpful to predict the outcomes of the
patients [2]. Despite the publication of this position paper
by the AASLD, differences in the definitions are still seen
in recent articles regarding acute liver failure [23], and
these differences hamper the conduct of reliable meta-
analyses.
Definition, classification, and diagnostic criteria
for fulminant hepatitis and acute liver failure in Japan
The definition and classification of fulminant hepatitis, the
representative disease entity associated with acute liver
failure in Japan, were established at the Inuyama Sympo-
sium in 1981 [3]. According to the Inuyama Symposium
criteria, patients with hepatitis were diagnosed as having
fulminant hepatitis when they developed grade II or more
severe hepatic encephalopathy due to severe liver damage,
as represented by prothrombin time values of B40 % of
the standardized value, within 8 weeks of the onset of the
hepatitis symptoms. Fulminant hepatitis was further
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classified into 2 clinical types; that is, the acute and sub-
acute types, on the basis of the hepatic encephalopathy
developing within 10 days or between 11 and 56 days,
respectively, after the onset of the hepatitis symptoms.
Fulminant hepatitis in Japan is defined as histological
evidence of hepatic inflammation, characterized by lym-
phocytic infiltration of the liver, associated with acute liver
failure. Thus, the etiology of fulminant hepatitis comprises
viral infections, including HBV carriers, autoimmune
hepatitis, drug allergy-induced liver injuries, and hepatitis
of indeterminate etiology.
The Intractable Liver Diseases Study Group of Japan,
supported by the Ministry of Health, Labour and Welfare,
last revised the diagnostic criteria for ‘‘fulminant hepatitis’’
in 2002 (Table 2) [1]. In this revision, 5 items clarifying
the inclusion and exclusion criteria for the diagnosis of
fulminant hepatitis were added as a footnote. We clarified
that patients with preexisting chronic liver diseases, such as
those with alcoholic hepatitis, were excluded from the
disease entity of fulminant hepatitis, whereas asymptom-
atic HBV carriers developing acute exacerbation of hepa-
titis were included as cases of fulminant hepatitis. Also, the
significance of histological evidence of liver inflammation
was emphasized, so that liver failure caused by drug or
chemical intoxication, circulatory disturbances, acute fatty
liver of pregnancy, Reye’s syndrome, or Wilson disease
were excluded from the diagnosis of fulminant hepatitis.
Moreover, the definitions of subtypes of fulminant hepatitis
were clarified; hepatitis patients with no or grade I
encephalopathy, but showing prothrombin time values of
B40 % of the standardized value were diagnosed as having
‘‘severe type of acute hepatitis’’, while those with grade II
or more severe hepatic encephalopathy developing
between 8 and 24 weeks after the disease symptoms onset,
with prothrombin time values of B40 % of the standard-
ized value were diagnosed as having LOHF. Thus, the
disease entity of LOHF in Japan differed from that in
Europe and the United States [14], because patients with no
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histological evidence of hepatitis and/or prothrombin time
values of [40 % of the standardized value were excluded
from the diagnosis of LOHF in Japan, even if they had
grade II or more severe hepatic encephalopathy.
In the revision conducted in 2002, however, the defini-
tion and concept of fulminant hepatitis were not modified,
because the diagnostic criteria established at the Inuyama
Symposium were useful to characterize the clinical features
of patients with acute liver failure in Japan. According to
the nationwide survey of fulminant hepatitis and LOHF
conducted by the Intractable Hepato-Biliary Diseases
Study Group in Japan (formally the Intractable Liver Dis-
eases Study Group of Japan), the clinical features of
patients differed markedly when the disease types were
defined based on the diagnostic criteria established in 1981 or
based on the revised criteria established in 2002. In this sur-
vey, 1,094 patients with fulminant hepatitis, consisting of 543
with the acute type and 551 with the subacute type of ful-
minant hepatitis were included, and 92 patients with LOHF
seen between 1998 and 2009 were enrolled [1, 24–29].
In regard to the etiology of hepatitis, viral infection
accounted for 67.4 and 30.9 % of the patients with the
acute and subacute types of fulminant hepatitis, respec-
tively, and for 10.9 % of the patients with LOHF. In most
patients with fulminant hepatitis caused by viral infection,
irrespective of the disease type, the causative agent was
HBV; transient HBV infection was more frequent in
patients with the acute type (39.2 %) as compared to the
subacute type (10.0 %) of fulminant hepatitis, while
the frequency of HBV carriers was greater in patients with
the subacute type (17.9 %) as compared to the acute type
(7.2 %) of fulminant hepatitis. Autoimmune hepatitis was
found in 1.8, 12.2, and 19.6 % of patients with the acute
and subacute types of fulminant hepatitis and LOHF,
respectively. Drug allergy-induced liver injury was seen in
9.0, 13.1, and 18.7 % of patients with the acute and
subacute types of fulminant hepatitis and LOHF, respec-
tively. It is noteworthy that the etiology was indeterminate
in 19.0, 40.8, and 40.2 % of patients with the acute and
subacute types of fulminant hepatitis and LOHF, respec-
tively. The outcomes of the patients also differed between
these disease types. The survival rates of patients receiving
medical treatment without liver transplantation were 53.7,
24.4, and 11.5 %, respectively, in patients with the acute
and subacute types of fulminant hepatitis and LOHF seen
between 1998 and 2003 [1], while these rates were 48.7,
24.2, and 13.0 %, respectively, in the corresponding cate-
gories of patients seen between 2004 and 2009 [24–29].
Although the diagnostic criteria for fulminant hepatitis
in Japan [1, 3] merit consideration in clinical practice for
the diagnosis of acute liver failure patients, they do need to
be revised to fit with the criteria for acute liver failure
adopted in Europe and the United States [2]. Thus, in 2006,
the Intractable Hepato-Biliary Diseases Study Group in
Japan constituted a task force to establish novel diagnostic
criteria for ‘‘acute liver failure’’, which includes the disease
entity ‘‘fulminant hepatitis’’. To establish such criteria for
defining ‘‘acute liver failure’’ in Japan, two types of
nationwide surveys were performed [30]; a survey of the
commercial kits used for the measurement of prothrombin
time at institutions to which hepatology specialists were
affiliated, and a survey of acute liver failure patients who
were excluded from the disease entities of fulminant hep-
atitis and LOHF. Consequently, ‘‘acute liver failure’’ in
Japan (Table 3) came to be defined as an acute liver disease
associated with prolongation of the prothrombin time, with
an INR of 1.5 or more. To confirm the correspondence
between the present criteria (Table 3) and previous criteria
(Table 2), ‘‘prothrombin time values ofB40 % of the
standardized value’’ was also employed as a cutoff to
define patients with acute liver failure. Patients without
hepatic encephalopathy were also included in the disease
Table 2 Diagnostic criteria for fulminant hepatitis in Japan established by the Intractable Liver Diseases Study Group of Japan, supported by the
Ministry of Health, Welfare and Labour (2003); from reference [1]
Fulminant hepatitis is defined as hepatitis with hepatic encephalopathy of grade II or more that develops in the patients within 8 weeks of the
onset of disease symptoms, associated with severe derangement of liver function, including prothrombin time values of less than 40 % of
the standardized value. Fulminant hepatitis is classified into 2 subtypes; the acute type and the subacute type, according to whether the
encephalopathy occurs within 10 days and later than 11 days, respectively, after the onset of the symptoms.
Note 1: Patients with chronic liver diseases are excluded from the disease entity of fulminant hepatitis, but asymptomatic hepatitis B virus
(HBV) carriers developing acute exacerbation are included as cases of fulminant hepatitis.
Note 2: Acute liver failure with no histological evidence of liver inflammation, such as that caused by drug or chemical intoxication,
circulatory disturbance, acute fatty liver of pregnancy, or Reye’s syndrome is excluded from the disease entity of fulminant hepatitis.
Note 3: The grading of hepatic encephalopathy is based on the criteria presented at the Inuyama Symposium in 1972.
Note 4: The etiology of fulminant hepatitis is based on the criteria established by the Intractable Liver Diseases Study Group of Japan in 2002.
Note 5: Patients with no or grade I encephalopathy, but showing prothrombin time values of less than 40 % of the standardized value are
diagnosed as having acute hepatitis, severe type. Patients in whom the encephalopathy develops between 8 and 24 weeks after the
disease onset, with prothrombin time values of less than 40 % of the standardized value are diagnosed as having late-onset hepatic
failure (LOHF). Both are diseases related to fulminant hepatitis, but are regarded differently from fulminant hepatitis.
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entity of acute liver failure, if they showed an INR of 1.5 or
more. Thus, acute liver failure patients are classified into
those with and without hepatic coma, and acute liver fail-
ure with hepatic coma is further subdivided into 2 disease
types; namely, the ‘‘acute type’’ and the ‘‘subacute type,’’
according to the interval from the onset of symptoms to the
development of hepatic encephalopathy, similar to the case
for fulminant hepatitis [1, 3].
Similar to the entity of acute liver failure in Europe and
the United States [2], in Japan patients without histological
evidence of inflammation in the liver, such as those with
the disease caused by drug toxicity, circulatory distur-
bances, or metabolic diseases are also included in the
disease entity of acute liver failure. In contrast, patients
showing impaired liver function due to underlying chronic
liver diseases before the worsening of the liver damage are
excluded from the disease entity of acute liver failure.
Thus, alcoholic liver disease patients are excluded from
this entity, because they show clinical features consistent
with acute-on-chronic liver disease. However, patients with
underlying chronic liver diseases such as fatty liver and
autoimmune hepatitis are included in the disease entity of
acute liver failure, when the liver function impairment is
retrospectively estimated to be minimal or absent prior to
the current exacerbation of the liver damage. Also, the
criteria for classification of hepatic encephalopathy and
etiology of hepatitis have been added as footnotes to the
present criteria (Tables 4, 5, 6). In addition, patients with
LOHF are defined as those showing prothrombin time
values of B40 % of the standardized value or INRs of 1.5
or more and grade II or more severe hepatic coma between
8 and 24 weeks of the onset of the disease symptoms, and
those without histological evidence of hepatitis are also
included in the disease entity of LOHF, similar to the case
of acute liver failure. On the other hand, the disease entity
of ‘‘acute hepatitis severe type’’ was excluded from the
footnote of the present criteria, because patients classified
under such a disease entity can also be diagnosed as having
‘‘acute liver failure without hepatic encephalopathy’’.
Nationwide survey of patients with acute liver failure
in Japan
Recently, the Intractable Hepato-Biliary Diseases Study
Group performed a nationwide survey of patients with
acute liver failure seen in 2010, in whom the diagnosis was
made according to the criteria published in 2011 [30]. The
Table 3 Diagnostic criteria for acute liver failure in Japan (2011); from reference [30]
Patients showing prothrombin time values of 40 % or less of the standardized value, or international normalized ratios (INRs) of 1.5 or more
due to severe liver damage within 8 weeks of the onset of disease symptoms are diagnosed as having ‘‘acute liver failure’’, where the liver
function prior to the current onset of liver damage is estimated to have been normal based on blood laboratory data and imaging
examinations. ‘‘Acute liver failure’’ is classified into ‘‘acute liver failure without hepatic coma’’ and ‘‘acute liver failure with hepatic coma’’;
no or grade I hepatic encephalopathy is present in the former type, while grade II or more severe hepatic encephalopathy is found in the
latter type. ‘‘Acute liver failure with hepatic coma’’ is further subclassified into 2 disease types; the ‘‘acute type’’ and ‘‘subacute type’’, with
grade II or more severe hepatic encephalopathy developing within 10 days or between 11 and 56 days after the onset of disease symptoms,
respectively, in the two types.
Note 1: Hepatitis B virus (HBV) carriers and autoimmune hepatitis patients showing acute exacerbation of hepatitis in the normal liver are
included under the disease entity of ‘‘acute liver failure’’. In the case of indeterminate previous liver function, the patients who are
HBV carriers and those with autoimmune hepatitis are diagnosed as having ‘‘acute liver failure’’ when no liver function impairment
preceding the exacerbation of the liver injury can be confirmed.
Note 2: In general, alcoholic hepatitis develops in patients with chronic liver diseases caused by habitual alcohol consumption. Thus, patients
with alcoholic hepatitis are excluded from the disease entity of ‘‘acute liver failure’’. However, patients with fatty liver caused by
alcohol intake and those with metabolic syndrome, including obesity, are diagnosed as having ‘‘acute liver failure’’ if etiologies other
than habitual alcohol consumption are responsible for the acute injury in the liver, in the absence of prior impairment of liver
function.
Note 3: Patients without histological evidence of hepatitis, such as inflammatory lymphocytic infiltration, are included under the disease entity
of ‘‘acute liver failure’’. Thus, patients with liver damage caused by drug toxicity, circulatory disturbance, or metabolic disease and
acute fatty liver of pregnancy are diagnosed as having ‘‘acute liver failure’’, while they are excluded from the disease entity of
‘‘fulminant hepatitis’’. In contrast, patients with liver injury caused by viral infection, autoimmune hepatitis, and drug allergy-induced
hepatitis are included under the disease entities of ‘‘fulminant hepatitis’’ and ‘‘acute liver failure’’.
Note 4: The severity of hepatic encephalopathy is diagnosed according to the classification presented at the Inuyama Symposium in 1972
(Table 4). Also, hepatic encephalopathy developing in pediatric patients and infants is classified according to the criteria proposed by
the 5th Workshop on Pediatric Liver Diseases in 1988 (Table 5).
Note 5: The etiology of ‘‘acute liver failure’’ is classified according to the criteria proposed by the Intractable Liver Diseases Study Group of
Japan in 2002, with some modifications (Table 6).
Note 6: Patients showing prothrombin time values of less than 40 % of the standardized value or INRs of 1.5 or more and grade II or more
severe hepatic coma between 8 and 24 weeks of the onset of disease symptoms are diagnosed as having late-onset hepatic failure
(LOHF), as a disease related to ‘‘acute liver failure’’.
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220 patients, consisting of 211 patients with acute liver
failure and 9 patients with LOHF, were enrolled from 742
institutions with specialists in the fields of hepatology,
gastroenterology, and/or acute medicine [31]. The 211
acute liver failure patients were classified into 96 (45.5 %)
without hepatic coma and 115 patients (54.5 %) with
hepatic coma, with the latter group being further divided
into 61 patients (28.9 %) with the acute type and
54 patients (25.6 %) with the subacute type (Fig. 1). Also,
the acute liver failure patients were classified into 188
patients (89.1 %) with hepatitis and 23 patients (10.9 %)
without hepatitis. The 188 patients with hepatitis consisted
of 85 patients (45.2 %) without hepatic coma, and 103
patients with hepatic coma (54.8 %), with 54 patients
(28.7 %) classified with the acute type and 49 patients
(26.1 %) classified with the subacute type. The 23 patients
without hepatitis were divided into 11 patients (47.8 %)
without hepatic coma and 12 patients (52.2 %) with hepatic
coma, including 7 (30.4 %) patients with the acute type and
5 (21.7 %) patients with the subacute type. In contrast, all
patients with LOHF presented with hepatic coma and were
classified as having the histological features of hepatitis
(Fig. 1).
The etiologies of liver damage in patients with acute
liver failure are shown in Fig. 2. Viral infection was
determined as the cause in 43 of 96 patients (44.8 %) with
acute liver failure without hepatic coma, 48 of 115 patients
(41.7 %) with acute liver failure with hepatic coma,
including 29 of 61 patients (47.5 %) with the acute type
and 19 of 54 patients (35.2 %) with the subacute type, and
3 of 9 patients (33.3 %) with LOHF. The percentage of
patients with liver injury caused by viral infections was
smaller than that reported from the previous nationwide
survey in Japan, especially in patients with acute type of
Table 4 Classification of
hepatic encephalopathy in adult
patients according to the grade
of hepatic coma proposed by the
Inuyama Symposium in 1972;
from reference [30]
Grade of coma Psychiatric disorders Reference items
I Inversion of sleep pattern
Euphoria and/or occasional depression
Negligent attitude with shortened attention span
Recognized retrospectively
in most cases
II Disorientation of time or place and confusion
Inappropriate behaviors, such as throwing
away money or discarding items of value
Occasional somnolent tendency; able to open
eyes and respond appropriately to questions
Makes impolite remarks, but follows
doctors’ instructions
Excitation state and, urinary and fecal
incontinence are absent, but
flapping tremor is found on physical
examination
III State of excitation and/or delirium, showing
defiant behavior
Somnolent tendency; sleeping most of the time
Opens eyes in response to stimulation, but cannot
follow the instructions of doctors, except
for simple orders
Flapping tremor is observed, and the
extent of disorientation is severe
IV Coma; complete loss of consciousness
Response to painful stimuli
Brushes off doctor’s hands if touched
and/or frowns in response to stimuli
V Deep coma
No response to painful stimuli
Table 5 Classification of hepatic encephalopathy in pediatric
patients and infants according to the grade of hepatic coma as pro-
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3 months after birth)
III Opens eyes in response to loud voice
IV Does not wake up in response to
painful stimuli, but frowns and/or brushes off
the item producing the stimulus with his/her hands
V No response to painful stimuli
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liver failure with hepatic coma [1, 24–29]. In most of the
cases of viral infection, the causative virus was HBV;
transient infection was predominant in patients without
hepatic coma and in those with acute-type liver failure with
coma, whereas the incidence of asymptomatic carriers
showing acute exacerbation of hepatitis was frequent in
patients with subacute-type liver failure with coma. It is
noteworthy that among the 25 asymptomatic carriers, there
were 9 patients with de-novo HBV hepatitis, with negative
test results for serum hepatitis B surface (HBs) antigen,
who developed acute liver failure following therapy with
immunosuppressive and/or anticancer drugs through an
increase of the serum HBV-DNA level.
Although a small number of patients with autoimmune
hepatitis and drug allergy-induced liver damage were
found among patients with each disease type, the etiology
of liver failure remained indeterminate in most of the
remaining patients, including 27 of 96 patients (28.1 %)
with acute liver failure without hepatic coma, 39 of 115
patients (33.9 %) with acute liver failure with coma
(including 17 of 61 patients [27.9 %] with the acute type
and 22 of 54 patients [40.7 %] with the subacute type of
liver failure), and 2 of 7 patients (22.2 %) with LOHF.
Etiologies other than hepatitis that may have induced liver
injury were found in 11 patients (11.5 %) with acute liver
failure without hepatic coma and in 12 patients (10.4 %)
with acute liver failure with hepatic coma (including 7
patients [11.5 %] with the acute type and 5 patients
[9.3 %] with the subacute type of acute liver failure),
while hepatitis was the cause of the liver injury in all the
patients with LOHF. The etiologies of liver damage other
than hepatitis were circulatory disturbance in 6 patients,
hepatic infiltration by malignant cells in 5 patients, post-
operative liver injuries in 4 patients, metabolic disease
in 3 patients, hemolytic-phagocytotic syndrome (HPS) in
3 patients, and drug toxicity-induced liver injury in
2 patients.
Among the 220 patients with acute liver failure and
LOHF, 29 (13.2 %) underwent liver transplantation and the
remaining 191 patients (86.8 %) were given conservative
medical treatment, including artificial liver support (con-
sisting of plasma exchange and hemodiafiltration). Liver
transplantation was performed only in patients with hepa-
titis, while all of the patients without histological evidence
of hepatitis received medical treatment alone. The survival
rate of the 191 patients managed by medical treatment
alone was 51.3 % (98/191), including 54.8 % (92/168) in
patients with hepatitis and 26.1 % (6/23) in patients with-
out hepatitis. In patients with hepatitis, the survival rate
was 86.7 % (72/83) in the patients without hepatic coma,
31.7 % (13/41) in the patients with acute-type liver failure
with coma, and 19.4 % (7/36) in the patients with suba-
cute-type liver failure with coma, and 0 % (0/8) in those
with LOHF; these values were greater than those in the
patients without hepatitis:45.5 % (5/11) in the patients
without hepatic coma, 14.3 % (1/7) in patients with acute-
type liver failure with coma, and 0 % (0/5) in patients with
subacute-type liver failure with coma. In contrast, the
survival rate in the patients treated by liver transplantation
was 62.1 % (18/29). The overall survival rate, including
the patients treated by liver transplantation, was 52.7 %
(116/220).
Table 6 Classification of etiologies of acute liver failure modified
from the criteria proposed by the Intractable Liver Diseases Study
Group of Japan in 2002; from reference [30]
I. Viral infection
1 Hepatitis A virus (HAV)
2 Hepatitis B virus (HBV)
(1) Transient infection
(2) Acute exacerbation in HBV carrier
i. Inactive carrier, without drug exposure
ii. Reactivation in inactive carrier by
immunosuppressant and/or anticancer drugs
iii. Reactivation in transiently infected patients
by immunosuppressant and/or anticancer drugs
(de-novo hepatitis)a
(3) Indeterminate infection patterns
3 Hepatitis C virus (HCV)
4 Hepatitis E virus (HEV)
5 Other viruses
II. Autoimmune hepatitis
III. Drug-induced liver injuries
1. Drug allergy-induced liver injury
2. Drug toxicity-induced liver injury
IV. Circulatory disturbance
V. Infiltration of the liver by malignant cells
VI. Metabolic diseases
VII. Liver injuries after liver resection and transplantation
VIII. Miscellaneous etiologies
IX. Indeterminate etiology despite sufficient examinations
X. Unclassified due to insufficient examinations
Patients with etiologies I, II, and III-1 are diagnosed as having
‘‘fulminant hepatitis’’ as well as ‘‘acute liver failure’’, whereas those
with etiologies III-2 and IV to VIII are diagnosed as having ‘‘acute
liver failure’’, but are excluded from the disease entity of ‘‘fulminant
hepatitis’’. Diagnostic criteria for the classification of etiology based
on laboratory data should be established in the future
a Serum hepatitis B surface (HBs) antigen-negative patients follow-
ing transient infection with HBV are classified as HBV carriers, in
whom HBV reactivation can be induced by immunosuppressant and/
or anticancer drugs; however, the significance of this causative eti-
ology needs to be evaluated further
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Outcome prediction models and guideline for liver
transplantation in patients with acute liver failure
Among the 220 patients with acute liver failure seen in
2010, 112 patients were diagnosed as having fulminant
hepatitis or LOHF with the histological features of hepatitis
[31]. The outcomes of these patients were as follows;
20 patients (17.9 %) and 65 patients (58.0 %), respectively,
survived and died with medical treatment alone, and 27
patients (24.1 %) underwent liver transplantation. Liver
transplantation is inevitable for the rescue of most patients
with acute liver failure, even in Japan, where artificial liver
support, including plasma exchange, is provided for almost
all patients. Thus, outcome prediction models with high
sensitivity and specificity levels were required to determine
the indications for liver transplantation.
Liver transplantation has been recognized as the stan-
dard therapy for patients with acute liver failure in Europe
and the United States since the 1980s [32, 33]. Bismuth







































Fig. 1 Classification of acute
liver failure patients in Japan
enrolled in a nationwide survey
performed by the Intractable
Hepato-Biliary Diseases Study
Group in Japan [31]. ALF acute
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Fig. 2 Etiology of acute liver
failure in Japanese patients
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performed by the Intractable
Hepato-Biliary Diseases Study
Group in Japan [31]. LOHF
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considered in patients with grade III or more severe hepatic
encephalopathy, with plasma coagulation factor V activity
levels of less than 20 % of the standardized values. Also,
Emond et al. [35] reported that patients with brain edema
due to encephalopathy, with prolongation of the pro-
thrombin time after 24 or 48 h of intensive medical care,
were candidates for liver transplantation. A similar out-
come prediction model was published by Bernuau et al.
[36] through multivariate analysis of the data of 115
patients with fulminant hepatitis due to HBV infection, in
which plasma factor V activity levels, status of disap-
pearance of HBs antigen, and the serum a-fetoprotein
concentration were selected as independent predictors of
survival. Moreover, in 1989, O’Grady et al. [37] published
a guideline with selection criteria for liver transplantation
in patients with acute liver failure, based on a multivariate
analysis of the data of 588 patients seen between 1973 and
1985. In this guideline, the prognosis was estimated dif-
ferently in patients with liver failure resulting from acet-
aminophen intoxication and in those with liver failure
resulting from viral hepatitis or drug allergy-induced liver
injury. In the former category of patients, the prognosis
was estimated based on 3 parameters; namely, the arterial
blood pH, peak prothrombin time, and the serum creatinine
level. In contrast, in the latter category of patients, the
prognosis was determined based on 5 parameters; namely,
etiology of the disease, age of the patient, duration of
jaundice before the onset of hepatic encephalopathy, peak
prothrombin time, and the serum bilirubin level. This
famous guideline, well known as the King’s College
Hospital criteria, was widely used around the world to
determine the indications for liver transplantation in
patients with acute liver failure [38–40]. Also, the useful-
ness of the model for end-stage liver disease (MELD),
which was originally established to evaluate the prognosis
of chronic liver failure patients [41], was assessed in
comparison with the predictive accuracy of the King’s
College Hospital criteria in patients with acute liver failure
[42–45].
However, the King’s College Hospital criteria were
found to be of limited usefulness for patients with ful-
minant hepatitis in Japan [46], and the predictive accuracy
of these criteria adopted for patients seen between 1993
and 1995 was found to be only 55 % for the assessment
conducted at the onset of hepatic encephalopathy, and
53 % for the assessment conducted on day 5 after the onset
of encephalopathy. Thus, a new guideline that could be
adopted for patients in Japan was established by Sugihara
et al., based on the results of a project undertaken by the
Acute Liver Failure Study Group of Japan in 1996 [46].
According to this guideline, the prognosis of patients with
fulminant hepatitis is estimated through a two-step proce-
dure (Table 7). First, the estimated prognosis is determined
at the onset of hepatic encephalopathy based on 5 param-
eters, with the parameters associated with a poor prognosis
being: (1) age older than 45 years, (2) interval of 11 or
more days from the onset of the initial disease symptoms to
the development of grade II or more severe hepatic
encephalopathy, (3) prothrombin time less than 10 % of the
standardized value, (4) serum bilirubin level of 18 mg/dL
or more, and (5) ratio of the serum direct to total bilirubin
levels of less than 0.67. Patients fulfilling 2 or more of the
above criteria, with the estimated prognosis of ‘‘death,’’ are
enrolled as candidates for liver transplantation. Then,
intensive therapy, including artificial liver support, is
administered to these patients for 5 days if possible, and
those showing improvement of both the prothrombin time
and encephalopathy grade are excluded from the list of
candidates for liver transplantation, with the estimated
prognosis changed to ‘‘alive’’. Such reassessment after
intensive treatment for 5 days seemed to improve the
prognostic accuracy of the guideline in fulminant hepatitis
patients in Japan, where artificial liver support can be
undertaken for more than 90 % of the patients [1, 24–29].
According to a prospective study, in which the guideline
was adopted for patients seen between 1993 and 1995, the
predictive accuracy of the guideline was 76 % for the first
assessment and 82 % for the reassessment [46]. On the
other hand, when the guideline was adopted for patients
seen between 1998 and 2003, the predictive accuracy was
even worse; the accuracy values in the patients not
receiving liver transplantation were 67 and 78 % among
Table 7 Guideline to determine the indications for liver transplan-
tation for patients with fulminant hepatitis and LOHF (published by
the Acute Liver Failure Study Group of Japan in 1996); from refer-
ences [46, 47]
Patients may be registered as potential recipients of liver
transplantation when at least 2 of the following 5 criteria are
satisfied at the time of the onset of grade II or more severe
hepatic encephalopathy
1. Age C45 years
2. Interval from the appearance of the initial symptoms to the
development of hepatic encephalopathy C11 days
3. Prothrombin time \10 % of the standardized value
4. Serum bilirubin concentration C18.0 mg/dL
5. Ratio of the direct to total bilirubin concentration \0.67
If liver transplantation cannot be performed within 5 days of the
onset of hepatic encephalopathy and intensive medical therapy,
including artificial liver support, is undertaken, the prognosis of
the patients is evaluated again. If both of the criteria listed below
are positive at 5 days after the onset of hepatic encephalopathy,
the prognosis is reassessed as ‘‘alive’’ and the patients are
excluded from the candidate list for liver transplantation
1. The hepatic encephalopathy shows improvement to grade I or
less or attenuation by 2 or more grades
2. Prothrombin time improves to over 50 % of the standardized
value
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those with acute and subacute types of fulminant hepatitis,
respectively, and the specificity of the guideline was
extremely low, especially in patients with the subacute type
of fulminant hepatitis [47]. Thus, the guideline to deter-
mine the indications for liver transplantation in acute liver
failure patients in Japan needs to be updated.
Accordingly, the task force of the Intractable Hepato-
Biliary Diseases Study Group established a novel scoring
system for predicting the outcomes of patients with ful-
minant hepatitis and LOHF in 2011, through analysis of the
data of 1,096 patients enrolled in a nationwide survey [48].
In this system, 6 parameters were identified and graded as
0, 1, or 2; the parameters were: the interval between disease
onset and the development of hepatic encephalopathy,
prothrombin time, total serum bilirubin concentration, ratio
of direct to total bilirubin concentration in the serum,
peripheral blood platelet count, and presence/absence of
liver atrophy (Table 8). The predicted mortality was
greater than 90 % in patients with a total score of 7 or
more, with predicted mortalities of 80–90, 70–80, and
50–60 % in those with a total score of 6, 5, and 4,
respectively, while the predicted mortality was less than
30 % in those with a total score of 3 or less. When the
prognosis of the patients with a total score of 5 or more was
judged as ‘‘death’’, the predictive accuracy was 0.80, with
sensitivity, specificity, positive predictive value (PPV), and
negative predictive value (NPV) of greater than 0.70 even
in the validation cohort [48].
Recently, we performed a cluster analysis of 1,022
patients with fulminant hepatitis and LOHF who were
enrolled in a nationwide survey between 1998 and 2007, to
evaluate the validity of the classification of acute liver
failure in Japan; we used a self-organizing map (SOM), a
data mining method that has been shown to be suitable for
analyses of complex multidimensional relationships [49].
The results of the analysis revealed that the patients could
be classified into three clusters, independent of the interval
between the disease symptoms onset and the development
of hepatic encephalopathy, with the clinical outcomes
differing markedly among the clusters [49]. This observa-
tion prompted us to postulate that data-mining methods
may be useful to revise the outcome prediction system, and
we established a decision-tree algorithm for prediction of
the prognosis of acute liver failure patients [50]. The out-
come of the patients at the onset of encephalopathy was
predicted based on 5 items: the patients were classified into
6 categories, with mortality rates ranging between 89 and
23 %. The outcome of the patients was also predicted
based on 7 items at 5 days after the onset of encephalop-
athy; the patients were classified into 8 categories with
mortality rates ranging between 100 and 11 %. Also, we
established outcome prediction models based on other
data-mining methods, such as radial basis function (RBF)
and back propagation (BP) (unpublished data). The use-
fulness of these models based on data-mining methods
needs to be further investigated.
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